تقرير
Brolucizumab after failure of aflibercept with photodynamic therapy in polypoidal choroidal vasculopathy: A case report.
| العنوان: | Brolucizumab after failure of aflibercept with photodynamic therapy in polypoidal choroidal vasculopathy: A case report. |
|---|---|
| المؤلفون: | Yuan PH; Faculty of Medicine, University of British Columbia, Vancouver (British Columbia), Canada., Khan HM; Faculty of Medicine, University of British Columbia, Vancouver (British Columbia), Canada., Sumita FAG; Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver (British Columbia), Canada; Division of Ophthalmology, University of São Paulo Medical School, São Paulo, Brazil. Electronic address: fernando-sumita@hotmail.com., Ribeiro Monteiro ML; Division of Ophthalmology, University of São Paulo Medical School, São Paulo, Brazil., Preti RC; Division of Ophthalmology, University of São Paulo Medical School, São Paulo, Brazil., Navajas EV; Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver (British Columbia), Canada. |
| المصدر: | Archivos de la Sociedad Espanola de Oftalmologia [Arch Soc Esp Oftalmol (Engl Ed)] 2023 Dec; Vol. 98 (12), pp. 713-717. Date of Electronic Publication: 2023 Nov 10. |
| نوع المنشور: | Case Reports |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier España Country of Publication: Spain NLM ID: 101715860 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2173-5794 (Electronic) Linking ISSN: 21735794 NLM ISO Abbreviation: Arch Soc Esp Oftalmol (Engl Ed) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Madrid : Elsevier España |
| مواضيع طبية MeSH: | Choroid Diseases*/drug therapy , Choroid Diseases*/complications , Photochemotherapy*, Humans ; Polypoidal Choroidal Vasculopathy |
| مستخلص: | We describe one case of polypoidal choroidal vasculopathy with persistent subretinal fluid despite multiple treatment with intravitreal Bevacizumab, Ranibizumab and Aflibercept, as well as Aflibercept associated with photodynamic therapy. The patient reached complete resolution after intravitreal Brolucizumab injection, but experienced recurrence of subretinal fluid 12 weeks after discontinuation. Brolucizumab might be an option in treating subretinal fluid after failure of other anti-VEGF agents associated with photodynamic therapy. (Copyright © 2023 Sociedad Española de Oftalmología. Published by Elsevier España, S.L.U. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Age-related macular degeneration; Brolucizumab; Choroidal polypoidal vasculopathy; Degeneración macular asociada a la edad; Líquido subretiniano; Photodynamic therapy; Subretinal fluid; Terapia fotodinámica; Vasculopatía coroidea polipoidea |
| المشرفين على المادة: | XSZ53G39H5 (brolucizumab) 15C2VL427D (aflibercept) |
| تواريخ الأحداث: | Date Created: 20231111 Date Completed: 20231204 Latest Revision: 20231204 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.oftale.2023.10.009 |
| PMID: | 37951353 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 2173-5794 |
|---|---|
| DOI: | 10.1016/j.oftale.2023.10.009 |